Anel de Ferrara & Keratoconus (Ferrara Ring Segment Implantation in Keratoconus)

 

Evaluation of a new nomogram for Ferrara ring segment implantation in keratoconus

Joaquín Fernández, Cristina Peris-Martínez, Antonio Pérez-Rueda et al

Int J Ophthalmol. 2021; 14(9): 1371–1383

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8403859/

 

Ferrara rings for visual rehabilitation in eyes with keratoconus and previous cross-linking using the Ferrara Ring nomogram

C A McLintock, J McKelvie, Y Li et al

Vision (Basel) 2021, vol 5 (4): 45

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8544695/

 

Refractive and visual outcomes after Ferrara corneal ring segment implantation at a 60% depth in keratoconic eyes: case series

A C Renesto, F E Hirai, M Campos

Arq Bras Oftalm 2019, vol 82 (6)

– Este estudo aborda os resultados refrativos, topográficos, acuidade visual e tomografia de coerência óptica, 12 meses após a inserção do segmento de Anel de Ferrara em túnel corneano a 60% de profundidade com o laser de femtosegundo, em pacientes com ceratocone.

– Série de casos não comparativos, prospectivos e intervencionistas. Realizamos a inserção do Anel de Ferrara através de incisão com o laser de femtosegundo em 15 olhos ceratocônicos. Foram incluídos pacientes com ceratocone documentado que voluntariamente assinaram consentimentos informados que tivessem melhor acuidade visual corrigida ≥0.30 tabela logMAR, espessura corneana ≥400µm. Foram excluídos pacientes com cirurgia ocular prévia ou curvatura corneana > 65 dioptrias (D). As principais variáveis medidas foram acuidade visual corrigida e os parâmetros topográficos da córnea (ceratometria mais plana (K1), mais curva (K2) e ceratometria média (K médio), avaliadas no pré-operatório e com 1, 3, 6 e 12 meses de seguimento.

– A média ± desvio padrão da acuidade visual sem correção e acuidade visual corrigida foi 1.03 ± 0.46 e 0.42 ± 0.13, respectivamente; o desvio padrão médio de 12 meses, a acuidade visual sem correção e acuidade visual corrigida foram de 0.72 ± 0.37 e 0.31 ± 0.16, respectivamente, sem diferenças significativas (p=0,05 para ambos). A melhora da acuidade visual corrigida foi estatisticamente significante após 3 meses (p=0,02), e após 6 meses (p=0,02). Os valores médios da linha de base K1, K2, e média (K médio) foram 48,35 ± 3,65D, 53,67 ± 3,38D, e 50,84 ± 3,36D, respectivamente. A média de 12 meses ± desvio padrão para K1, K2, e K médio foi 46,53 ± 3,70D, 49,83 ± 3,50 D, e 48,12 ± 3,49D respectivamente, com diferença estatisticamente significativas para todos os 3 parâmetros topográficos (p=0,01).

– Conclusões: a inserção do Anel de Ferrara a uma profundidade de 60% no estroma corneano produz resultados visuais, refracionais e ceratométricos satisfatórios em olhos com ceratocone.

https://www.scielo.br/j/abo/a/rHHDhF6WG5gXHXDwLgT4nJP/?lang=en

 

Evaluation of keratoconus progression and visual improvement after intrastromal corneal ring segments implantation: a retrospective study

B K Moscovici, P F Rodrigues, R A Rodrigues

European Journal of Ophthalmology march 2021

Objective: To investigate the role of ICRS in halting keratoconus progression in a large sample of patients.

– Methods: A retrospective, non-comparative, interventional study based on the review of medical records of patients diagnosed with keratoconus who underwent Ferrara corneal ring segment implantation. A retrospective chart analysis study of 123 operated eyes with follow-up ranging from 3 to 16 years (mean 5.3 ± 3.6 years) was performed. This study was carried out at Ocular Surgery Unit, São Paulo, Brazil. All topographic data were obtained from Pentacam (Oculus, Arlington, USA). The same surgeon performed all surgeries, and the Ferrara ICRS nomogram was used for ICRS selection in all cases.

– Results: Corrected distance visual acuity, keratometry, and topographic astigmatism improved in most cases, with statistical significance. In 42 eyes (53.8%), there was an increase in K1 or K2, and in 36 (46.2%), there was a reduction or maintenance in K1. Considering a difference higher than 1 D, between 3-month post-surgery and final visit (group 3), 32 eyes (41%) showed an increase, and 46 eyes (59%) ended equal or below this value.

The implantation of ICRS showed improvement in visual and keratometric indexes. The majority of patients did not increase more than one diopter in keratometric values after ICRS implantation. ICRS may be effective for slowing disease progression, especially in older patients

https://journals.sagepub.com/doi/abs/10.1177/11206721211000646

 

Intrastromal corneal ring segment implantation in 409 paracentral keratoconic eyes

L F Cueto, C Lisa, A Poo-López et al

Cornea 2016, vol 35 (11): 1421-1426

https://pubmed.ncbi.nlm.nih.gov/27490048/

 

Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: fevereiro 2022

 

 

Retinoblastoma 2022

 

O retinoblastoma é um tumor maligno ocular com mais frequência na infância e pode causar cegueira e morte.

possui uma incidência de um a cada 15 ou 30.000 nascidos

 

– O retinoblastoma possui uma incidência de um a cada 15 ou 30.000 nascidos vivos, aproximadamente 3% em crianças menores de dois anos de idade e 5% em crianças maiores de cinco anos de idade.

 

– Cerca de 25% apresentam tumor bilateral (hereditário); outros 15% em processo unilateral e hereditário; e 60% com doença unilateral e não hereditária.

 

 

Recent advancements in the management of retinoblastoma and uveal melanoma

Amy C Schefler, Ryan S Kim

Fac Rev. 2021; 10: 51.

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8204763/

 

Changes in treatment patterns and globe salvage rate of advanced retinoblastoma in Korea: efficacy of intra-arterial chemotherapy

Dong Hyun Lee, Jung Woo Han, Seung Min Hahn et al

J Clin Med. 2021 Nov; 10(22): 5421

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8619482/

 

At what age could screening for familial retinoblastoma be discontined? A systematic review

Milo van Hoefen Wijsard, Saskia H. Serné, René H. Otten et al

Cancers (Basel) 2021 Apr; 13(8): 1942

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8072927/

 

Current indications of secondary enucleation in retinoblastoma management: a pósiton paper on Behalf of the European Retinoblastoma Group

Christina Stathopoulos, Livia Lumbroso-Le Rouic, Annette C. Moll et al

Cancers (Basel) 2021 Jul; 13(14): 3392

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8303810/

 

Introduction of a variant classification system for analysis of genotype-phenotype relationship in heritable retinoblastoma

Isabel Hülsenbeck, Mirjam Frank, Eva Biewald,et al

Cancers (Basel) 2021 Apr; 13(7): 1605

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8037437/

 

 

Whole-genome sequencing of retinoblastoma reveals the diversity of rearrangements disrupting RB1 and uncovers a treatment-related mutational signatures

Helen R. Davies, Kevin D. Broad, Zerrin Onadim et al

Cancers (Basel) 2021 Feb; 13(4): 754

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7918943/

 

Qumioterapia intrarterial para el manejo del retinoblastoma

J C Gómez-Veja, M I Ocampo-Navia, J José Botero-Trujillo et al

Univ Med 2021, vol 62 (4)

http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2011-08392021000400007&lng=en&nrm=iso&tlng=es

 

Retrato de familiares acompanhantes de crianças e adolescentes atendidos por retinoblastoma no Brasil: Estudo transversal

M I P Messias, G S Bochi, A N F da Silva et al

Research, Society & Development 2021, vol 10 (5)

https://rsdjournal.org/index.php/rsd/article/view/15096/13503

 

Long-term of subsequente cancer incidence among hereditary and nonhereditary retinoblastoma survivors

Sara J. Schonfeld, Ruth A. Kleinerman, David H. Abramson et al

Br J Cancer. 2021 Mar 30; 124(7): 1312–1319

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8007574/

 

Benign tumors in long-term survivors of retinoblastoma

Milo van Hoefen Wijsard, Sara J. Schonfeld, Flora E. van Leeuwen et al

Cancers (Basel) 2021 Apr; 13(8): 1773

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8068196/

 

Subsequent malignant neoplasms in retinoblastoma survivors

Armida W. M. Fabius, Milo van Hoefen Wijsard, Flora E. van Leeuwen, Annette C. Moll

Cancers (Basel) 2021 Mar; 13(6): 1200

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8001190/

 

Parenteral occupation and risk of chilhood retinoblastoma in Denmark

Negar Omidakhsh, Johnni Hansen, Beate Ritz, et al

J Occup Environ Med. 2021 Mar 1; 63(3): 256–261

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8259454/

 

The impact of cell-free DNA analysis on the management of retinoblastoma

Amy Gerrish, Helen Jenkinson, Trevor Cole

Cancers (Basel) 2021 Apr; 13(7): 157

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8037190/

 

Multi-functionalized nanomaterials and nanoparticles for diagnosis and treatment of retinoblastoma

Rabia Arshad, Mahmood Barani, Abbas Rahdar,et al

Biosensors (Basel) 2021 Apr; 11(4): 9

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8066896/

 

A hign-risk retinoblastoma subtype with stmnes features, dedifferentiated cone states and neuronal/ganglion cell gene expression.

Jing Liu, Daniela Ottaviani, Meriem Sefta et al

Nat Commun. 2021; 12: 5578

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8458383/

 

Response criteria for intraocular retinoblastoma: RB-RECIST

Jesse L. Berry, Francis L. Munier, Brenda L. Gallie et al

Pediatr Blood Cancer. 2021 May; 68(5): e28964

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8049511/

 

Retinoblastoma from human stem cell-derived retinal organoids

Jackie L. Norrie, Anjana Nityanandam, Karen Lai,  et al

Nat Commun. 2021; 12: 4535

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8316454/

 

A single arm study of systemic and sub-Tenon chemotherapy for groups C and D intraocular retinoblastoma, a Children´s Oncology Group Study (ARET 0231)

Rima F. Jubran, Judith G. Villablanca, Mark Krailo et al

Pediatr Blood Cancer. 2020 Sep; 67(9): e28502

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7857974/

 

Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: janeiro 2022